Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

The combined therapy with chondroitin sulfate plus glucosamine sulfate or chondroitin sulfate plus glucosamine hydrochloride does not improve joint damage in an experimental model of knee osteoarthritis in rabbits.

Roman-Blas JA, Mediero A, Tardío L, Portal-Nuñez S, Gratal P, Herrero-Beaumont G, Largo R.

Eur J Pharmacol. 2017 Jan 5;794:8-14. doi: 10.1016/j.ejphar.2016.11.015. Epub 2016 Nov 12.

PMID:
27845067
2.

O-linked N-acetylglucosamine (O-GlcNAc) protein modification is increased in the cartilage of patients with knee osteoarthritis.

Tardio L, Andrés-Bergós J, Zachara NE, Larrañaga-Vera A, Rodriguez-Villar C, Herrero-Beaumont G, Largo R.

Osteoarthritis Cartilage. 2014 Feb;22(2):259-63. doi: 10.1016/j.joca.2013.12.001. Epub 2013 Dec 12.

3.

The increase in O-linked N-acetylglucosamine protein modification stimulates chondrogenic differentiation both in vitro and in vivo.

Andrés-Bergós J, Tardio L, Larranaga-Vera A, Gómez R, Herrero-Beaumont G, Largo R.

J Biol Chem. 2012 Sep 28;287(40):33615-28. Epub 2012 Aug 2.

4.

RANKL synthesized by articular chondrocytes contributes to juxta-articular bone loss in chronic arthritis.

Martínez-Calatrava MJ, Prieto-Potín I, Roman-Blas JA, Tardio L, Largo R, Herrero-Beaumont G.

Arthritis Res Ther. 2012 Jun 18;14(3):R149. doi: 10.1186/ar3884.

5.

Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer.

Martoni AA, Di Fabio F, Pinto C, Castellucci P, Pini S, Ceccarelli C, Cuicchi D, Iacopino B, Di Tullio P, Giaquinta S, Tardio L, Lombardi R, Fanti S, Cola B.

Ann Oncol. 2011 Mar;22(3):650-6. doi: 10.1093/annonc/mdq433. Epub 2010 Sep 16.

PMID:
20847032
6.

Nonsteroidal antiinflammatory drugs and prostaglandin E(2) modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis.

Moreno-Rubio J, Herrero-Beaumont G, Tardio L, Alvarez-Soria MA, Largo R.

Arthritis Rheum. 2010 Feb;62(2):478-88. doi: 10.1002/art.27204.

7.

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE, Zhang WG, Mahoney R, Gaydos C, Tardio L, Kim SK, Conant R, Curran K, Kaplan J, Verheijen J, Ayral-Kaloustian S, Mansour TS, Abraham RT, Zask A, Gibbons JJ.

Cancer Res. 2010 Jan 15;70(2):621-31. doi: 10.1158/0008-5472.CAN-09-2340. Epub 2010 Jan 12.

8.

In vitro and in vivo activities of novel 6-methylidene penems as beta-lactamase inhibitors.

Weiss WJ, Petersen PJ, Murphy TM, Tardio L, Yang Y, Bradford PA, Venkatesan AM, Abe T, Isoda T, Mihira A, Ushirogochi H, Takasake T, Projan S, O'Connell J, Mansour TS.

Antimicrob Agents Chemother. 2004 Dec;48(12):4589-96.

9.

Effect of srtA and srtB gene expression on the virulence of Staphylococcus aureus in animal models of infection.

Weiss WJ, Lenoy E, Murphy T, Tardio L, Burgio P, Projan SJ, Schneewind O, Alksne L.

J Antimicrob Chemother. 2004 Mar;53(3):480-6. Epub 2004 Feb 4.

PMID:
14762051

Supplemental Content

Loading ...
Support Center